BridgeMD
New treatment option for Limb Pain, Phantom
Official title A Study of Contralateral Limb Block
ClinicalTrials.gov ID: NCT06045936
What this study is testing
What is Lidocaine?
Lidocaine is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for limb pain, phantom.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This research is being done to determine if an anesthetic like Lidocaine, may be effective when injected around the sciatic nerve of the intact limb in patients with limb loss pain on the contralateral side.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Lower extremity amputation performed more than 12 months before study enrollment
- PLP/RLP in affected amputated limb \> 4 on NRS26
- Pain duration of more than 6 months despite a trial of conservative therapies for at least 2 months, including oral medications, topical medicines...
- Willingness to undergo image guided diagnostic nerve block
You likely can't join if
- Refusal / inability to participate or provide consent
- Contraindications to diagnostic nerve block
- Non-neurogenic source of PLP/RLP
- Current opioid use \> 50 morphine milligram equivalents per day
- Any treatment pain treatment in the residual limb within the last 30 days
- Severe uncontrolled medical condition (i.e., hypertensive crisis, decompensated hypothyroidism)
See the full eligibility criteria
- Lower extremity amputation performed more than 12 months before study enrollment
- PLP/RLP in affected amputated limb \> 4 on NRS26
- Pain duration of more than 6 months despite a trial of conservative therapies for at least 2 months, including oral medications, topical medicines, physical therapy, and physical modalities (i.e., heat, cold...
- Willingness to undergo image guided diagnostic nerve block
- Refusal / inability to participate or provide consent
- Contraindications to diagnostic nerve block
- Non-neurogenic source of PLP/RLP
- Current opioid use \> 50 morphine milligram equivalents per day
- Any treatment pain treatment in the residual limb within the last 30 days
- Severe uncontrolled medical condition (i.e., hypertensive crisis, decompensated hypothyroidism)
- Use of investigational pain drug within past 30 days or other concurrent clinical trial enrollment
The study team makes the final eligibility decision.
Where it's taking place
- Mankato, Minnesota, United States
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mankato, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.